North America Stress Relief Supplements Market Size & Outlook, 2025-2033
North America Stress Relief Supplements Market Insights
- As per Deep Market Insights insights, North America’s Stress Relief Supplements Market was valued at USD 192.49 Million in 2024 and is anticipated to expand to USD 325.34 Million by 2033.
- From 2026 to 2033, the market is anticipated to expand at a CAGR of 5.99%.
- Within Ingredient, L-theanine accounted for the largest market size in 2024.
- During the forecast period, GABA is anticipated to remain the highest-growth segment within the Ingredient category.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- The global Stress Relief Supplements Market size saw North America holding a share of 32% in 2024.
- United States is forecasted to account for the leading share of the global market by 2033.
- In North America, Canada is forecasted to be the fastest-expanding market, projected to reach USD 90.03 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 192.49 Million |
| Market Size In 2033 | USD 325.34 Million |
| Largest segment | L-theanine |
| Units | Revenue in USD Million |
| CAGR | 5.99% (2025-2033) |
| Segmnetation Covered | |
| North America |
|
| Ingredient |
|
| Format |
|
| Target |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
North America Stress Relief Supplements Market Country 2025-2033 (USD Million)
| North America | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | XX.x | XX.x | XX.x | 139.82 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Canada | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
North America Stress Relief Supplements Market Ingredient 2025-2033 (USD Million)
| Ingredient | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L-theanine | XX.x | XX.x | XX.x | 88.35 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| GABA | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Magnesium | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Adaptogen blends | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
North America Stress Relief Supplements Market Format 2025-2033 (USD Million)
| Format | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capsule | XX.x | XX.x | XX.x | 90.12 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gummy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Drink | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
North America Stress Relief Supplements Market Target 2025-2033 (USD Million)
| Target | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Work | XX.x | XX.x | XX.x | 122.05 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Sleep support | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.